Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

Next Previous
X
Search
Trial Profile

Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Catequentinib (Primary) ; Irinotecan (Primary) ; Vincristine (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 23 Dec 2021 Results (n=35) assessing health-related quality of life and the benefit-risk in quality-adjusted survival published in the Medicine
    • 01 Jul 2021 Results (n=41)assessing the safety and efficacy of anlotinib, vincristine, andirinotecan (AVI) in patients with advanced EWS published in the Oncologist
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top